Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel

Ashley Fowlkes, Alon Peretz, David Greenberg, Avital Hirsch, Emily T. Martin, Min Z. Levine, Laura Edwards, Sarah Radke, Adam S. Lauring, Jill M. Ferdinands, Chao Zhang, Young M. Yoo, Jacob Dreiher, Gabriella Newes‐Adeyi, Eduardo Azziz‐Baumgartner, Alicia M. Fry, Arnold S. Monto, Ran D. Balicer, Mark G. Thompson, Mark A. KatzInternational Journal of Infectious Diseases 2024 · DOI

TL;DR

This study investigated whether a newer recombinant influenza vaccine (RIV4) offers superior immune responses compared to the traditional egg-based vaccine (IIV4) in healthcare professionals (HCP) in Israel. The findings suggest RIV4 elicits a stronger antibody response across most influenza strains, even in individuals who are frequently vaccinated, potentially offering better protection.

What Problem Does This Paper Address?

Annual influenza vaccination is crucial for healthcare personnel (HCP) due to their high occupational exposure and risk of transmitting the virus to vulnerable patients. While influenza vaccines generally reduce infection risk, some studies indicate that frequent vaccination can lead to a diminished serologic response and reduced vaccine effectiveness over time. Furthermore, the manufacturing process for traditional egg-based inactivated influenza vaccines can sometimes lead to a mismatch with circulating influenza strains, particularly for the A(H3N2) subtype. To address these issues, "enhanced" influenza vaccines, such as recombinant vaccines that don't rely on eggs and may contain higher antigen doses, have been developed. However, there's a need to understand how these enhanced vaccines perform in populations that are already frequently vaccinated, like HCP, and whether they can overcome the potential "blunting" effect of repeated vaccinations. This paper aims to fill that gap by directly comparing the immunogenicity of a recombinant influenza vaccine (RIV4) against a standard egg-based vaccine (IIV4) in frequently vaccinated Israeli HCP.

Methods

The researchers conducted a randomized, open-label immunogenicity trial involving healthcare personnel (HCP) from two Israeli hospitals. Participants were randomly assigned to receive either a quadrivalent recombinant influenza vaccine (RIV4) or a standard-dose quadrivalent inactivated influenza vaccine (IIV4). The study focused on comparing the immune responses, specifically antibody titers, one month after vaccination. Key measurements included:

  • Hemagglutination Inhibition (HAI) antibody titers: This is a standard method to measure the body's immune response to influenza viruses.
  • Seroconversion rate: The proportion of participants who showed at least a four-fold increase in antibody titers from before to after vaccination.
  • Mean Fold Rise (MFR): The average increase in antibody titers.
  • Geometric Mean Titer (GMT) ratios: This compares the average antibody levels between the RIV4 and IIV4 groups.

The study also performed subgroup analyses to examine the impact of vaccination history (frequent vs. infrequent vaccination over the past five years, and vaccination in the immediately preceding season) on the immune response.

Datasets

The study utilized serum samples collected from 415 healthcare personnel (HCP) in Israel during the 2019-2020 influenza season. These samples were collected pre-vaccination and approximately 21-35 days post-vaccination. The data was supplemented by participants' electronic medical records, which provided information on socio-demographic characteristics, comorbidities, and past influenza vaccination history.

Key Insights and Ideas

  • RIV4's Superiority: The recombinant vaccine (RIV4) consistently demonstrated a stronger antibody response compared to the egg-based vaccine (IIV4) across most influenza strains tested. This suggests RIV4 might offer a more robust and potentially more effective immune shield.
  • Overcoming Vaccination History: Even in individuals who had received influenza vaccines multiple times in previous years, RIV4 still elicited a significantly higher immune response. This is crucial because frequent vaccination can sometimes lead to diminished responses to traditional vaccines.
  • A(H3N2) Advantage: The difference in immune response was particularly notable for the A(H3N2) strain, where RIV4 showed a more pronounced advantage, especially when using cell-based virus assays. This aligns with the known challenges of egg-based vaccine matching for this subtype.
  • Potential for Broader Protection: While not a direct measure of effectiveness, higher immunogenicity is generally associated with better protection. The findings suggest RIV4 could be a valuable tool for enhancing influenza protection, particularly in high-risk groups like HCP.

Key Results

  • Overall GMT Ratios: The GMT ratio comparing RIV4 to IIV4 was 2.0 for A(H1N1)pdm09, 1.6 for A(H3N2) (egg-based), 1.8 for B(Yamagata), and 1.1 for B(Victoria). For A(H3N2) (cell-based), the ratio was even higher at 2.3.
  • Seroconversion Rates: RIV4 recipients showed significantly higher seroconversion rates for A(H1N1)pdm09 (52.8% vs. 23.8%) and A(H3N2) (57.2% vs. 34.8% for egg-based, and 77.4% vs. 41.0% for cell-based).
  • High Titers: A greater proportion of RIV4 recipients achieved high antibody titers (≥160) for A(H1N1)pdm09 (66.3% vs. 38.9%) and A(H3N2) (egg-based: 16.7% vs. 0%; cell-based: 34.9% vs. 0%).
  • Frequent Vaccinees: Even among frequently vaccinated HCP, RIV4 generally showed higher GMT ratios compared to IIV4, with ratios ranging from 1.4 to 3.3, except for B(Victoria).

Limitations and Future Work

The authors acknowledge several limitations:

  • Shipping Delay: A delay in vaccine shipping meant some HCP were vaccinated outside the study's intended timeframe, though both groups were impacted similarly.
  • Age Difference: RIV4 recipients were slightly older than IIV4 recipients, although the impact of immunosenescence was considered minimized due to the age range of participants.
  • Microneutralization Assay Subset: The microneutralization assays for A(H3N2) were performed on a subset of participants, which reduced the precision of those specific results.
  • Serum Collection Timing: While the ideal timing for serum collection was 21-35 days post-vaccination, a wider window was allowed due to operational challenges, though this variation did not significantly differ between groups.
  • No NA Glycoprotein Data: The study did not assess immune responses to the neuraminidase (NA) glycoprotein, as RIV4 does not contain NA.

Future work should focus on evaluating the vaccine effectiveness (VE) of RIV4 in real-world settings, particularly in diverse populations and across subsequent seasons. Further studies are also needed to determine the sustainability of RIV4's immunogenicity with repeated annual vaccinations.

Summary updated

Abstract

NCT04523324.
BibTeX
@article{fowlkes2024randomised,
  author = {Ashley Fowlkes and Alon Peretz and David Greenberg and Avital Hirsch and Emily T. Martin and Min Z. Levine and Laura Edwards and Sarah Radke and Adam S. Lauring and Jill M. Ferdinands and Chao Zhang and Young M. Yoo and Jacob Dreiher and Gabriella Newes‐Adeyi and Eduardo Azziz‐Baumgartner and Alicia M. Fry and Arnold S. Monto and Ran D. Balicer and Mark G. Thompson and Mark A. Katz},
  title = {{Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel}},
  journal = {International Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1016/j.ijid.2024.107260},
}
Figure